In this issue:
CRBN SNPs as predictors of adverse effects with thalidomide-based therapy for MM
Daratumumab retreatment in refractory MM
First cycle response predicts long-term response to lenalidomide/dexamethasone in relapsed/refractory MM
Upfront VRD vs. VCD in MM
Once- vs. twice-weekly carfilzomib in newly diagnosed MM
MM response kinetics in the novel agent era
Daratumumab + dexamethasone for triple-refractory MM
Bortezomib consolidation after SCT in younger and older patients with new MM
Pembrolizumab/lenalidomide/dexamethasone for MM
Selectively targeting MM with BCMA-specific central memory CD8+ cytotoxic T-cells
Please login below to download this issue (PDF)